Search Results

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company, Radionetics Radionetics aims to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the Crinetics’ Core Nonpeptide Platform and Includes Drug Candidates and Leads Against 10 Oncology Targets – Radionetics Frazier Healthcare Partners, today announced the formation of an independently operated new company, Radionetics Radionetics aims to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the

heart failure drug following reverse merger with Avrobio Lilly signs $140M upfront partnership with Radionetics

They are ligands labeled with radioactive isotopes which can be used in binding assays to quantify other Another common radioactive atom, 125I, with a higher specific activity, but a shorter half-life (60 days

Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.

Celtarys develops fluorescently labeled ligands designed for real-time, non-radioactive GPCR assays—enabling GPCR Functional Assay Fluorescent GTPγS enables sensitive, non-radioactive GPCR activity assays for drug

Celtarys Research , a biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive